Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,410 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03571308 | A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)(ACCEPT) | completed | Phase 1 / Phase 2 | 39 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05238558 | Safety and Immune Response to FMPV-1 | completed | Phase 1 | 16 | Hubro Therapeutics ASINDUSTRY | 1 | Sep 21, 2023 |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | terminated | Phase 1 / Phase 2 | 23 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 13, 2023 | clinicaltrials |
| NCT03317496 | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 67 | PfizerINDUSTRY | 8 | Aug 29, 2023 | clinicaltrials |
| NCT02277717 | First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients | completed | Phase 1 | 185 | Byondis B.V.INDUSTRY | 4 | Aug 14, 2023 | clinicaltrials |
| NCT05129280 | A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors | terminated | Phase 1 | 23 | Hoffmann-La RocheINDUSTRY | 6 | Aug 4, 2023 | clinicaltrials |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy | terminated | Phase 1 / Phase 2 | 8 | GenmabINDUSTRY | 3 | Aug 3, 2023 | clinicaltrials |
| NCT01054625 | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 4 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | terminated | Phase 1 / Phase 2 | 40 | IpsenINDUSTRY | 8 | Jul 19, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT02432274 | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma | completed | Phase 1 / Phase 2 | 117 | Eisai LimitedINDUSTRY | 6 | Jul 11, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05397184 | Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)(TvT CAR7) | unknown | Phase 1 | 10 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT04194034 | Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 15 | TransgeneINDUSTRY | 2 | Jun 23, 2023 | clinicaltrials |
| NCT00121719 | An Open Label Dose Escalation Study Of E7080 | completed | Phase 1 | 82 | Eisai Inc.INDUSTRY | 2 | Jun 22, 2023 | clinicaltrials |
| NCT01559818 | A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 | terminated | Phase 1 / Phase 2 | 10 | Immodulon Therapeutics LtdINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02797977 | A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects | completed | Phase 1 / Phase 2 | 153 | Sierra Oncology LLC - a GSK companyINDUSTRY | 2 | Jun 22, 2023 | clinicaltrials |
| NCT02893189 | CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation(CARD) | completed | Phase 1 | 17 | University College, LondonOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02797964 | A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | completed | Phase 1 / Phase 2 | 107 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00481091 | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 60 | AbbVieINDUSTRY | 4 | Jun 13, 2023 | clinicaltrials |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | completed | Phase 1 / Phase 2 | 136 | pharmaand GmbHINDUSTRY | 5 | Jun 9, 2023 | clinicaltrials |
| NCT03521037 | Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor | completed | Phase 1 | 16 | pharmaand GmbHINDUSTRY | 3 | Jun 9, 2023 | clinicaltrials |
| NCT01009190 | A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens | completed | Phase 1 | 85 | pharmaand GmbHINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT02546921 | Phase I Study of MOv18 IgE | completed | Phase 1 | 26 | Cancer Research UKOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | completed | Phase 1 | 143 | AbbVieINDUSTRY | 8 | May 22, 2023 | clinicaltrials |
| NCT03892018 | The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol | terminated | Phase 1 | 29 | Athenex, Inc.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT02351765 | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers(ABC-08) | completed | Phase 1 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia(SeluDex) | terminated | Phase 1 / Phase 2 | 12 | University of BirminghamOTHER | 3 | May 11, 2023 | clinicaltrials |
| NCT01397929 | An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 73 | Basilea PharmaceuticaINDUSTRY | 1 | May 10, 2023 | clinicaltrials |
| NCT02043665 | CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)(STORM) | completed | Phase 1 | 85 | ViralyticsINDUSTRY | 3 | May 6, 2023 | clinicaltrials |
| NCT02431988 | Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation(COBALT) | completed | Phase 1 | 10 | University College, LondonOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT01160926 | Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial(DREAMtherapy) | terminated | Phase 1 | 31 | The Christie NHS Foundation TrustOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT04893551 | A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants | terminated | Phase 1 | 16 | BerGenBio ASAINDUSTRY | 4 | Apr 20, 2023 | clinicaltrials |
| NCT01493453 | A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy(CD19) | terminated | Phase 1 | 17 | The Christie NHS Foundation TrustOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | withdrawn | Phase 1 | 0 | University of OxfordOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | completed | Phase 1 / Phase 2 | 146 | Immunocore LtdINDUSTRY | 5 | Mar 21, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT02561988 | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | completed | Phase 1 | 86 | Blueprint Medicines CorporationINDUSTRY | 2 | Mar 17, 2023 | clinicaltrials |
| NCT05187858 | A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 | 15 | Lupin Ltd.INDUSTRY | 3 | Mar 17, 2023 | clinicaltrials |
| NCT02278250 | First in Human Study of M4344 in Participants With Advanced Solid Tumors | completed | Phase 1 | 97 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 4 | Mar 16, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03916744 | A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 | 75 | Genentech, Inc.INDUSTRY | 5 | Mar 10, 2023 | clinicaltrials |
| NCT02581631 | An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas(CheckMate 436) | completed | Phase 1 / Phase 2 | 145 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 7, 2023 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials